R8404

Rufinamide

≥98% (HPLC), powder

• Synonyme(s) : 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
• Formule empirique (notation de Hill) : C₁₀H₈F₂N₄O
• Numéro CAS: 106308-44-5
• Poids moléculaire : 238.19
• NACRES: NA.77
• PubChem Substance ID: 24724595
• UNSPSC Code: 12352200
• MDL number: MFCD00865314
• Assay: ≥98% (HPLC)
• Form: powder

Propriétés

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white
• solubility: DMSO: 9 mg/mL
• originator: Novartis
• storage temp.: −20°C
• SMILES string: NC(=O)c1cn(Cc2c(F)cccc2F)nn1
• InChI: 1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
• InChI key: POGQSBRIGCQNEG-UHFFFAOYSA-N
• Gene Information: human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

Description

General description

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem/physiol Actions

Broad-spectrum anticonvulsant.

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• pictograms: GHS08,GHS07
• signalword: Warning
• hcodes: H336,H351,H361fd
• pcodes: P202 - P261 - P271 - P280 - P304 + P340 + P312 - P308 + P313
• Hazard Classifications: Carc. 2 - Repr. 2 - STOT SE 3
• target_organs: Central nervous system
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable